M3 (EU)

M3 Acquires MirVracha LCC in Russia Launching Full-Scale Development of Physician Platform Business in Russia

M3, Inc. (Headquarters: Tokyo, Japan; CEO: Itaru Tanimura; URL: https://corporate.m3.com/; “M3” below) has announced the acquisition of MirVracha LCC (Headquarters: Moscow, Russia; CEO: Shotaro Yamamoto; “MirVracha” below), a website provider for healthcare professionals in Russia.   M3 operates m3.com, a specialized web portal for medical professionals that delivers healthcare related information to its 300,000+ physician members in Japan. Presence outside of Japan includes the U.S., U.K., France, China, Korea and India, with aggressive business expansion overseas that has amassed over 6 million physicians as members across its global platforms.   This allows provision of services including marketing support, marketing research, and job placement support that leverage the platform’s powerful value as a media channel. MirVracha operates the medical professional website "МирВрача" with over 400,000 medical professional members, equivalent to roughly 60% of all physicians in Russia, and mainly provides marketing support services for pharmaceutical companies.   Since its founding by Shotaro Yamamoto in 2011, MirVracha has focused on building a quality network of healthcare professionals as well as improving content creation capabilities, and is now utilized by major Russian pharmaceutical companies to provide drug and disease information. In 2012, M3 entered into a capital and business alliance that includes the licensing of the MR-kun service, and have since developed a strong relationship with MirVracha through provision of support and know-how surrounding business launches and operations. M3 has completed the acquisition of MirVracha as a subsidiary, and will leverage its experience and know-how gained through its overseas business development in the United States, Europe, Asia, and other regions.   M3 will move forward with the full-scale development of services related to its physician platform in Russia by combining the high-quality network of physicians, medical institutions, and pharmaceutical companies that MirVracha has cultivated in Russia, with M3's expertise in operating websites and various services for healthcare professionals.

M3 announces further expansion into Europe and Latin America with the acquisition of Vidal Group

M3 is strengthening and growing its global operations with the acquisition of Vidal Group, a trusted provider of prescribing information and clinical decision support services to doctors and other HCPs in key markets including France, Germany, Spain and Latin America. This move complements M3’s existing business activities in Japan, the United States, United Kingdom, China, Korea and India.

UK's department of Health deploys information campaign to ensure continued vigilance over Ebola

Paul Rice and Simon Walker join M3 (EU) as the company announces strong double-digit growth…

M3, the global healthcare technology company with brands including Doctors.net.uk, medeConnect, M3 Global Research, Rotamaster and The Vidal Group has announced two significant appointments in Paul Rice who joins as Chief Operating Officer, and Simon Walker who takes on a Business Director role. This news comes as M3 Inc. releases its 2016 full-year results, with year-on-year revenue growing by 21%, and continued strong growth in key markets across Europe, US, Japan, China, Korea and India, and with membership of M3’s 100% verified physician communities now at over 4 million members.

Learning to invest in doctors’ education

Pharmaceutical companies know doctors want high-value educational content. In a highly pressurised, cost-constrained healthcare environment with increasing demands for value and improved patient outcomes, time-poor doctors are calling out for more educational resources. However, the industry can find it hard to make a break from traditional methods of engaging with doctors, such as promotional communications and the traditional sales representative call to hospitals and GP surgeries.

Engaging doctors around the globe

Embedding a digital strategy as a prominent part of a pharmaceutical marketing campaign is becoming ever more important. Despite some perceived reluctance on the part of the industry, pharmaceutical companies are now exploring and exploiting a myriad of different digital channels in order to deliver content to, and engage with, their target audiences.

How do doctors spend their time online?

In our recent research piece, Doctor networks: The rules of engagement for pharma, some overarching principles for online engagement between the pharmaceutical industry and doctors were defined.

How do doctors want to engage with pharma on new products?

More than 80% of European doctors agree they are interested in staying up-to-date with new developments about pharmaceutical products. But what influences their choice of treatment and how do they prefer to receive product information?

Revolutionising the Digital Content Delivery Model

Pharmaceutical industry processes don’t have to make the delivery of marketing campaigns slow and unmanageable, and thus ineffective. Changing working practices and really, truly thinking differently about how to deliver materials in a new and faster way is possible, but only if companies are ready to consider and embrace new, novel ways of working. Utilising these methods, M3 reduced a client's delivery time from 75 days to just 7.5 days

Healthcare in the Digital Age

Healthcare is changing. By understanding the needs of the physicians, and using innovative channels to make meaningful connections, pharma can ensure it continues to enjoy a mutually beneficial relationship.

Doctors.net.uk